Amphastar P Stock Today

AMPH Stock  USD 35.70  0.04  0.11%   

Performance

0 of 100

 
Weak
 
Strong
Very Weak

Odds Of Distress

Less than 2

 
High
 
Low
Very Low
Amphastar is trading at 35.70 as of the 18th of January 2025. This is a 0.11% increase since the beginning of the trading day. The stock's open price was 35.66. Amphastar has a very small chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 29th of January 2023 and ending today, the 18th of January 2025. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
25th of June 2014
Category
Healthcare
Classification
Health Care
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California. The company has 48.08 M outstanding shares of which 4.82 M shares are presently shorted by private and institutional investors with about 7.83 trading days to cover. More on Amphastar P

Moving together with Amphastar Stock

  0.63EQ EquilliumPairCorr
  0.7ME 23Andme HoldingPairCorr
  0.74VALN Valneva SE ADRPairCorr

Moving against Amphastar Stock

  0.85DRTS Alpha Tau MedicalPairCorr
  0.79DYAI Dyadic InternationalPairCorr
  0.79SRZNW Surrozen WarrantPairCorr
  0.76VCEL Vericel Corp OrdPairCorr
  0.76CDIOW Cardio DiagnosticsPairCorr
  0.72DMAC DiaMedica TherapeuticsPairCorr
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores

Amphastar Stock Highlights

ESG Sustainability
Environmental
Governance
Social
Old NameAggregated Micro Power Hldg
Business ConcentrationPharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, SP Small-Cap 600, NASDAQ Biotechnology, NASDAQ Composite Total, NASDAQ Health Care, Health Care, Pharmaceuticals, Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors)
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.650.49
Significantly Up
Slightly volatile
Gross Profit Margin0.310.49
Way Down
Slightly volatile
Total Current Liabilities272.2 M259.2 M
Sufficiently Up
Slightly volatile
Non Current Liabilities Total782.6 M745.3 M
Sufficiently Up
Slightly volatile
Total Assets1.8 B1.7 B
Sufficiently Up
Slightly volatile
Total Current Assets591.2 M563 M
Sufficiently Up
Slightly volatile
Debt Levels
Amphastar can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Amphastar's financial leverage. It provides some insight into what part of Amphastar's total assets is financed by creditors.
Liquidity
Amphastar P currently holds 623.64 M in liabilities with Debt to Equity (D/E) ratio of 0.21, which may suggest the company is not taking enough advantage from borrowing. Amphastar P has a current ratio of 3.57, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Amphastar's use of debt, we should always consider it together with its cash and equity.

Stock Based Compensation

15.91 Million
Amphastar P (AMPH) is traded on NASDAQ Exchange in USA. It is located in 11570 6th Street, Rancho Cucamonga, CA, United States, 91730 and employs 1,761 people. Amphastar is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.74 B. Amphastar P conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 48.08 M outstanding shares of which 4.82 M shares are presently shorted by private and institutional investors with about 7.83 trading days to cover. Amphastar P currently holds about 183.39 M in cash with 183.5 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.74.
Check Amphastar Probability Of Bankruptcy
Ownership Allocation
Amphastar holds a total of 48.08 Million outstanding shares. The majority of Amphastar P outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Amphastar P to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Amphastar. Please pay attention to any change in the institutional holdings of Amphastar P as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Amphastar Ownership Details

Amphastar Stock Institutional Holders

InstituionRecorded OnShares
American Century Companies Inc2024-09-30
639.6 K
Northern Trust Corp2024-09-30
583.4 K
T. Rowe Price Associates, Inc.2024-09-30
568.9 K
Marshall Wace Asset Management Ltd2024-09-30
568.5 K
Btim Corp2024-09-30
539.6 K
Renaissance Technologies Corp2024-09-30
489.4 K
Bessemer Group Inc2024-09-30
477 K
Goldman Sachs Group Inc2024-09-30
449.4 K
Mesirow Institutional Investment Management, Inc.2024-09-30
413.9 K
Blackrock Inc2024-09-30
M
Vanguard Group Inc2024-09-30
2.7 M
View Amphastar Diagnostics

Amphastar Historical Income Statement

As of now, Amphastar's Total Revenue is increasing as compared to previous years. The Amphastar's current Gross Profit is estimated to increase to about 424 M, while Selling General Administrative is projected to decrease to under 46.2 M. View More Fundamentals

Amphastar Stock Against Markets

Amphastar Corporate Management

Ziping LuoChief ChairmanProfile
Peter LangoshVP AuditProfile
MBA MPHExecutive OperationsProfile
MP MBASenior OperationsProfile
Rong MSSenior ProductionProfile
Dan MBASenior CommunicationProfile

Already Invested in Amphastar P?

The danger of trading Amphastar P is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Amphastar is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Amphastar. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Amphastar P is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Amphastar P offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Amphastar's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Amphastar P Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Amphastar P Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Amphastar P. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.
You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amphastar. If investors know Amphastar will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Amphastar listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.14)
Earnings Share
2.96
Revenue Per Share
14.942
Quarterly Revenue Growth
0.059
Return On Assets
0.0867
The market value of Amphastar P is measured differently than its book value, which is the value of Amphastar that is recorded on the company's balance sheet. Investors also form their own opinion of Amphastar's value that differs from its market value or its book value, called intrinsic value, which is Amphastar's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amphastar's market value can be influenced by many factors that don't directly affect Amphastar's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Amphastar's value and its price as these two are different measures arrived at by different means. Investors typically determine if Amphastar is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amphastar's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.